The U.S. Food and Drug Administration has approved Eli Lilly’s Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 years and older with moderate-to-severe atopic dermatitis.
This article was originally published on MedicalXpress.com
FDA approves Ebglyss for moderate-to-severe atopic dermatitis
You may also be interested in:
The Latest
Will a nutritional supplement help you run better?
Whether you jog to keep fit or compete in marathons, the physically demanding sport of running can deplete the body of essential nutrients. During a race like a half-marathon, a runner’s metabolism — or ability […]
The Latest
5 Popular Supplements in Canada for Optimal Health and Wellness
As a health and wellness enthusiast, I have always been interested in the role of supplements in promoting optimal health. In Canada, there are many supplements available on the market, each with different benefits and […]
The Latest
Why you should stop buying vitamins and get more sleep instead
Almost half of all Canadians regularly take at least one nutritional supplement such as vitamins, minerals, fibre supplements, antacids and fish oils. Many of these individuals are healthy and hoping to improve general well-being or prevent chronic […]
Read More:
-
2% of all children nationwide—had lost a family member to a drug overdose as of 2019, according to a study by researchers at the USC [...]
-
Fluoride helps prevent tooth decay and makes your child’s teeth stronger. Fluoride can be found in drinking water, food and beverages, toothpaste, mouth rinses and [...]
-
The American Academy of Pediatrics encourages parents and caregivers to read aloud with their newborns and young children as an opportunity to foster loving, nurturing [...]
